Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback